Table 2.
Univariable and multivariable overall survival analyses.
| OS (Events/Pts = 57/87) | Univariable | Multivariable | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | Adjusted HR (95% CI) | P value | P value (LR test) | |
| PIK3α | |||||
| Low | 1 | 1 | 0·006 | ||
| High | 2·09 (1·12–3·91) | 0·02 | 2·77 (1·41–5·46) | 0·003 | |
| Age at diagnosis | |||||
| ≤60 | 1 | 1 | 0·002 | ||
| >60 | 2·91 (1·64–5·17) | <0·001 | 3·35 (1·53–7·31) | 0·002 | |
| IPI score | |||||
| Low (0–2) | 1 | 1 | 0·006 | ||
| High (3–5) | 3·02 (1·62–5·63) | 0·001 | 2·58 (1·31–5·09) | 0·006 | |
| Not evaluated | 1·81 (0·85–3·83) | 0·1 | 2·85 (1·26–6·45) | 0·01 | |
| Disease type | |||||
| Non‐NKTCL | 1 | 1 | 0·002 | ||
| NKTCL | 2·04 (1·12–3·71) | 0·02 | 3·23 (1·57–6·64) | 0·001 | |
| Anthracycline‐based chemo in first line | |||||
| No | 1 | 1 | 0·01 | ||
| Yes | 0·27 (0·15–0·49) | <0·001 | 0·38 (0·20–0·71) | 0·003 | |
| Unknown | 0·31 (0·07–1·32) | 0·1 | 0·53 (0·11–2·55) | 0·4 | |
| ECOG | |||||
| 0–1 | 1 | ||||
| 2–4 | 4·55 (1·94–10·66) | <0·001 | |||
| Unknown | 1·18 (0·61–2·27) | 0·6 | |||
| Elevated LDH | |||||
| No | 1 | ||||
| Yes | 1·86 (0·87–3·96) | 0·1 | |||
| Unknown | 1·49 (0·39–5·65) | 0·6 | |||
| PTEN | |||||
| Low | 1 | ||||
| High | 0·30 (0·07–1·21) | 0·09 | |||
| Gender | |||||
| Female | 1 | ||||
| Male | 1·67 (0·90–3·11) | 0·1 | |||
| Stage | |||||
| I–II | 1 | ||||
| III–IV | 1·61 (0·88–2·94) | 0·1 | |||
| PIK3‐β | |||||
| Negative | 1 | ||||
| Positive | 0·59 (0·27–1·33) | 0·2 | |||
| PIK3δ | |||||
| Low | 1 | ||||
| High | 0·66 (0·38–1·14) | 0·1 | |||
| PIK3γ | |||||
| Negative | 1 | ||||
| Positive | 1·15 (0·67–1·96) | 0·6 | |||
P value calculated using a Wald test or likelihood ratio test (indicated by LR test). IPI, International Prognostic Index; NKTCL, natural killer/T‐cell lymphoma; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.